No Data
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH): intends to promote a restricted stock incentive plan of 8.0878 million shares.
Gelonghui reported on March 28 that Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) announced a restrictive stock incentive plan for 2025. The total number of restricted stocks to be granted under this incentive plan is 8.0878 million shares, accounting for approximately 4.06% of the total share capital of 199.430865 million shares on the announcement date of this incentive plan. The total number of individuals to be granted incentive stocks for the first time under this plan is 559. The granting price for the restricted stocks for the initial recipients is 12.14 yuan per share.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Gibbel: Gibel 2024 Annual Results Express Announcement
Gibel 2024 Annual Results Express Announcement
Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH): Not yet connected to the AI platform.
On February 18, Glonghui reported that Jiangsu Jibeier Pharmaceutical Co., Ltd. (688566.SH) stated on the investor interaction platform that according to the company's preparation and disclosure plan for the 2024 annual report, the annual report will be disclosed on April 15, 2025. The company will disclose the 2024 annual performance report in accordance with relevant regulations by the end of February 2025, please pay attention. According to the company's current plan, the Phase III clinical trial for the new antidepressant JJH201501 is expected to complete the enrollment of subjects by the end of March 2025, and after enrollment, follow-up observations and data sorting will be conducted, with the completion of Phase III expected by the end of 2025.
Could The Market Be Wrong About Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHSE:688566) Given Its Attractive Financial Prospects?
